Sweden's Nanexa Q4 revenue jumps

Reuters

02/19

Overview

Sweden drug delivery firm reported Q4 revenue up significantly yr/yr
Company announced license and option agreement with Moderna
Company converted 8.5 mln warrants into shares, raising SEK 17 mln

Outlook

Nanexa sees favorable conditions for 2026 due to Moderna agreement

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		SEK 30.09 mln
Q4 EPS		SEK 0.10
Q4 Net Income		SEK 16.04 mln
Q4 EBIT		SEK 16.67 mln

Analyst Coverage

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nMFN95N9Bn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612816470"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612816470\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612816470?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 15:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612816470","market":"nz","top_or_hot":-1,"title":"Sweden's Nanexa Q4 revenue jumps","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Nanexa Q4 revenue jumps </title></head><body>Overview<ul><li>Sweden drug delivery firm reported Q4 revenue up significantly yr/yr</li><li>Company announced license and option agreement with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a></li><li>Company converted 8.5 mln warrants into shares, raising SEK 17 mln</li></ul>Outlook<ul><li>Nanexa sees favorable conditions for 2026 due to Moderna agreement</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q4 Revenue</td><td></td><td>SEK 30.09 mln</td><td></td></tr><tr><td>Q4 EPS</td><td></td><td>SEK 0.10</td><td></td></tr><tr><td>Q4 Net Income</td><td></td><td>SEK 16.04 mln</td><td></td></tr><tr><td>Q4 EBIT</td><td></td><td>SEK 16.67 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago</li></ul>Press Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's Nanexa Q4 revenue jumps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's Nanexa Q4 revenue jumps\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2026-02-19 15:13\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Nanexa Q4 revenue jumps </title></head><body>Overview<ul><li>Sweden drug delivery firm reported Q4 revenue up significantly yr/yr</li><li>Company announced license and option agreement with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a></li><li>Company converted 8.5 mln warrants into shares, raising SEK 17 mln</li></ul>Outlook<ul><li>Nanexa sees favorable conditions for 2026 due to Moderna agreement</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q4 Revenue</td><td></td><td>SEK 30.09 mln</td><td></td></tr><tr><td>Q4 EPS</td><td></td><td>SEK 0.10</td><td></td></tr><tr><td>Q4 Net Income</td><td></td><td>SEK 16.04 mln</td><td></td></tr><tr><td>Q4 EBIT</td><td></td><td>SEK 16.67 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago</li></ul>Press Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL1N3ZF099:1","article_id":"2612816470","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612816470","pubTimestamp":1771485219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's Nanexa Q4 revenue jumpsOverviewSweden drug delivery firm reported Q4 revenue up significantly yr/yrCompany announced license and option agreement with ModernaCompany converted 8.5 mln warrant","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4501":"段永平概念","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4551":"寇图资本持仓"},"translate_title":"瑞典Nanexa第四季度收入猛增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Sweden's Nanexa Q4 revenue jumps OverviewSweden drug delivery firm reported Q4 revenue up significantly yr/yrCompany announced license and option agreement with ModernaCompany converted 8.5 mln warrants into shares, raising SEK 17 mlnOutlookNanexa sees favorable conditions for 2026 due to Moderna agreementKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueSEK 30.09 mlnQ4 EPSSEK 0.10Q4 Net IncomeSEK 16.04 mlnQ4 EBITSEK 16.67 mlnAnalyst CoverageThe stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months agoPress Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}